ClinicalTrials.gg
CompletedNCT02725476Updated Dec 7, 2018Results posted

Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

A Phase 2 interventional study of XmAb5871 in IgG4-RD, sponsored by Xencor, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-12-07.

Sponsored by Xencor, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Immunoglobulin G4-Related Disease with a site in United States — 4 open to participants now, 7 under way, 3 of them phase 3. Immunoglobulin G4-Related Disease · United States.

Enrollment
6th of 12
20 · median 18
Started
2016
with 1 other
Phase 2
7 of 14
1 open now
Registered
3rd of 14
by date

Among the 14 studies in Immunoglobulin G4-Related Disease with a site in United States, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2016, is one of 7 in phase 2, and was the 3rd registered.

Immunoglobulin G4-Related Disease

72 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

4 of the 14 studies in Immunoglobulin G4-Related Disease with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Immunoglobulin G4-Related Disease studies recruiting now, 12 (43%) set no upper age limit and 13 (46%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Immunoglobulin G4-Related Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity

03

Conditions studied

  • IgG4-RD
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active IgG4-RD
  • Compatible pattern of organ involvement consistent with IgG4-RD that cannot be attributed to other causes
  • Histopathologically-proven diagnosis of IgG4-RD
  • Peripheral blood plasmablast count >900 cells/mL and/or elevated IgG4-RD levels during screening
  • Able and willing to complete the entire study according to the study schedule
  • Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • History or evidence of a clinically unstable/uncontrolled disorder, condition or disease other than IgG4-RD that, in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation, procedures or completion
  • within 5 years (except successfully treated in situ cervical cancer, resected squamous cell or basal cell carcinoma of the skin, or prostate cancer with no recurrence ≥3 years following prostatectomy)
  • Presence of recurrent or chronic infections, defined as ≥3 infections requiring antimicrobials over the past 6 months prior to screening
  • Active infection requiring hospitalization or treatment with parenteral antimicrobials within the 60 days prior to randomization or oral antimicrobials within the 21 days prior to enrollment
  • Patient is taking >40 mg of prednisone QD
  • Prior use of rituximab (or other B cell depleting agents) within 6 months of enrollment. Prior use of any B cell depleting agent greater than 6 months from enrollment is allowed if the CD19+ B cell count is within the normal reference range during screening
  • Use of any agent within 5 half-lives of the agent (or 6 months if the half-life is unknown) prior to enrollment
  • agent use within the three months prior to enrollment
  • Has received within 2 months of enrollment
  • Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to end-of-study visit
  • Unable or unwilling to partake in the follow-up assessments or required protocol procedures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    XmAb5871

    XmAb5871 administered by IV infusion for up to a total of 12 infusions

    Biological: XmAb5871

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With an Improvement in IgG4-RD Activity

    Improvement of disease activity as defined by a decrease of IgG4-RD responder index \>= 2 points from Day 1 pre-dose disease activity score. The IgG4-RD Responder Index Total Activity Score ranges from 0 to a maximum of 162. Higher scores represent greater (i.e. worse) disease activity. A score of 0 represents no disease activity other than residual fibrosis.

    Time frame: Baseline Day 1 to Day 169

Secondary outcomes

  1. Number of Patients Experiencing a Treatment-emergent Adverse Event as Assessed by CTCAE v4.3

    The number of patients experiencing a treatment-emergent adverse event as assessed by CTCAE v4.3 will be tabulated according to MedDRA system-organ class and preferred term, intensity and causality.

    Time frame: Baseline Day 1 to Day 197

07

Results

Posted Dec 7, 2018
Limitations and caveats
The fixed-dose group was added by amendment to collect information on fixed IV doses with bioequivalence to subcutaneous doses planned for future studies. This group is not intended for efficacy or safety comparisons to the initial 15 participants.

Participant flow

Participant flow — Overall Study
MilestoneXmAb5871 5 mg/kgXmAb5871 Fixed Dose
Started155
Completed124
Not completed31
Withdrew: Physician decision20
Withdrew: Adverse event11

Outcome measures

PrimaryProportion of Patients With an Improvement in IgG4-RD Activity

Improvement of disease activity as defined by a decrease of IgG4-RD responder index \>= 2 points from Day 1 pre-dose disease activity score. The IgG4-RD Responder Index Total Activity Score ranges from 0 to a maximum of 162. Higher scores represent greater (i.e. worse) disease activity. A score of 0 represents no disease activity other than residual fibrosis.

Time frame:
Baseline Day 1 to Day 169
Reported as:
Count of participants · Participants
Proportion of Patients With an Improvement in IgG4-RD Activity
ParticipantsXmAb5871 5 mg/kgXmAb5871 Fixed Dose
Responder at Day 169 visit124
Non-Responder at Day 169 visit20
Not Assessed at Day 169 visit11
SecondaryNumber of Patients Experiencing a Treatment-emergent Adverse Event as Assessed by CTCAE v4.3

The number of patients experiencing a treatment-emergent adverse event as assessed by CTCAE v4.3 will be tabulated according to MedDRA system-organ class and preferred term, intensity and causality.

Time frame:
Baseline Day 1 to Day 197
Reported as:
Count of participants · Participants
Number of Patients Experiencing a Treatment-emergent Adverse Event as Assessed by CTCAE v4.3
ParticipantsXmAb5871 5 mg/kgXmAb5871 Fixed Dose
Number of Patients Experiencing a Treatment-emergent Adverse Event as Assessed by CTCAE v4.3135

Adverse events

Collected over Day 1 (First Dose) through Day 197. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
XmAb5871 5 mg/kg0/15 (0%)1/15 (6.7%)7/15 (46.7%)
XmAb5871 Fixed Dose0/5 (0%)1/5 (20%)3/5 (60%)
Most frequent serious events
Most frequent serious events
EventXmAb5871 5 mg/kgXmAb5871 Fixed Dose
Chronic inflammatory demyelinating polyradiculoneuropathyNervous system disorders0/151/5
Chronic lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/151/5
PneumoniaInfections and infestations1/150/5
Most frequent other events
Most frequent other events
EventXmAb5871 5 mg/kgXmAb5871 Fixed Dose
NauseaGastrointestinal disorders2/152/5
VomitingGastrointestinal disorders1/152/5
Upper respiratory tract infectionInfections and infestations0/152/5
Abdominal painGastrointestinal disorders3/151/5
Nasal congestionRespiratory, thoracic and mediastinal disorders1/151/5
DiarrhoeaGastrointestinal disorders2/150/5
ChillsGeneral disorders2/150/5
HeadacheNervous system disorders2/150/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)XmAb5871 5 mg/kgXmAb5871 Fixed DoseTotal
Mean60.1 ± 10.5751.2 ± 14.1157.9 ± 11.82
Sex: Female, Male
Sex: Female, Male(Participants)XmAb5871 5 mg/kgXmAb5871 Fixed DoseTotal
Female516
Male10414
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)XmAb5871 5 mg/kgXmAb5871 Fixed DoseTotal
Hispanic or Latino000
Not Hispanic or Latino15520
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)XmAb5871 5 mg/kgXmAb5871 Fixed DoseTotal
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American123
White12315
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)XmAb5871 5 mg/kgXmAb5871 Fixed DoseTotal
United States15520
Serum IgG4 level at Baseline
Serum IgG4 level at Baseline(mg/dL)XmAb5871 5 mg/kgXmAb5871 Fixed DoseTotal
Mean440.33 ± 622.990858.60 ± 351.608544.90 ± 588.674
Involved Areas at Baseline
Involved Areas at Baseline(Participants)XmAb5871 5 mg/kgXmAb5871 Fixed DoseTotal
Bile Ducts202
Constitutional Symptoms617
Heart / Pericardium303
Kidney516
Lacrimal Glands7310
Lungs426
Lymph Nodes10414
Nasal Cavity Lesion303
Orbital Lesion213
Other448
Other ENT Lesions, e.g. tonsillitis, pharyngitis202
Other Salivary Glands101
Pancreas134
Parotid Glands8210
Retroperitoneal Fibrosis112
Sinusitis224
Skin011
Submandibular Glands9312
Baseline IgG4-RD Responder Index Total Activity Score
Baseline IgG4-RD Responder Index Total Activity Score(Total Activity Score)XmAb5871 5 mg/kgXmAb5871 Fixed DoseTotal
Mean11.5 ± 6.6512.8 ± 6.4211.8 ± 6.45
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Dec 2017, 21 months.

Results were first posted in Dec 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2016
First posted
Apr 1, 2016
StartActual
Mar 2016
Primary completionActual
Dec 2017
CompletionActual
Dec 2017
Results first posted
Dec 7, 2018
Last update
Dec 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02725476
Lead sponsor
Xencor, Inc.
Responsible party
Sponsor
First posted
Apr 1, 2016
Start date
Mar 2016
Primary completion
Dec 2017
Completion
Dec 2017
Results posted
Dec 7, 2018
Last update
Dec 7, 2018

Study contacts

John Stone, M.D., M.P.H.
principal investigator · Rheumatology Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obexelimab

Start the discussion